治疗过程中的复发性或耐药性造血性恶性瘤患者的未来准备:一种定性研究
Kazuko Akashi1, Yoshie Imai2, Shingen Nakamura3
1Department of Nursing, Fuchu Hospital, Osaka, Japan; Graduate School of Biomedical Sciences, The University of Tokushima, Tokushima, Japan.
Annals of palliative medicine
|February 18, 2025
概括
患有复发性/耐药性血液恶性瘤的患者面临困难的治疗决策. 了解他们的动机是关键,以使护理与个人价值观和偏好保持一致,以便更好地规划生命的终点.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 抚慰性护理是一种缓解性护理.
- 患者为中心的医学
背景情况:
- 复发性或耐药性 (R/R) 血液性恶性瘤需要强化治疗,如干细胞移植和CAR-T细胞治疗.
- 这些治疗方法带有重大风险和症状负担,但患者经常积极地追求它们,寻求潜在的治疗或缓解.
- 了解患者的动机对于将侵略性治疗与个人价值观和偏好保持一致至关重要.
研究的目的:
- 探索R/R血液性恶性瘤患者如何为未来做好准备,并确定治疗目标.
- 识别患者的动机和偏好,以支持个性化的决策.
- 在有限的选择和不确定的预测的背景下,为关于未来护理规划的早期讨论提供基础.
主要方法:
- 一个定性描述性研究.
- 与16名患者进行了半结构面试.
- 参与者患有复发性/耐药性造血性恶性瘤,并入院接受化疗.
主要成果:
- 患者叙述中出现了四个主要主题:
- 主题一:愿意忍受治疗,尽管复苏前景困难.
- 主题二:治疗决策取决于身体的耐力.
- 主题III:承认个人局限性,同时保持尝试的意愿.
- 主题IV:为了他人潜在的利益而继续进行治疗.
结论:
- 患有R/R血液性恶性瘤的患者表现出继续治疗的各种动机.
- 关于患者的目标和愿望的公开沟通对于确保治疗与患者的偏好保持一致至关重要.
- 这种理解支持以患者为中心的护理和瘤学中的共享决策.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Bone Marrow Sampling and Transplants
275
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
275


